R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2016, CA: A Cancer Journal for Clinicians, vol.66, issue.1, pp.7-30, 2016.

S. V. Rajkumar, V. Rajkumar, R. A. Kyle, M. Van-duin, P. Sonneveld et al., Multiple Myeloma, Current Problems in Cancer, vol.33, issue.1, pp.7-64, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00557757

D. Kazandjian, Multiple myeloma epidemiology and survival: A unique malignancy, Seminars in Oncology, vol.43, issue.6, pp.676-681, 2016.

W. Wang, Y. Zhang, R. Chen, Z. Tian, Y. Zhai et al., Chromosomal instability and acquired drug resistance in multiple myeloma, Oncotarget, vol.8, issue.44, pp.78234-78244, 2017.

P. Moreau, How I treat myeloma with new agents, Blood, vol.130, issue.13, pp.1507-1513, 2017.

A. K. Nooka, N. S. Joseph, J. L. Kaufman, L. T. Heffner, V. A. Gupta et al., Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re?treatment with daratumumab among refractory patients, Cancer, vol.125, issue.17, pp.2991-3000, 2019.

J. Wijdenes, W. C. Vooijs, C. Clément, J. Post, F. Morard et al., A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-323, 1996.

S. Supiot, A. Faivre-chauvet, O. Couturier, M. F. Heymann, N. Robillard et al., Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.94, issue.S4, pp.1202-1209, 2002.

I. B. Bayer-garner, R. D. Sanderson, M. V. Dhodapkar, R. B. Owens, and C. S. Wilson, Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions, Modern Pathology, vol.14, issue.10, pp.1052-1058, 2001.

R. Gharbaran, Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies, Critical Reviews in Oncology/Hematology, vol.94, issue.1, pp.1-17, 2015.

J. Pouget and S. J. Mather, General aspects of the cellular response to low- and high-LET radiation, European Journal of Nuclear Medicine, vol.28, issue.4, pp.541-561, 2001.

S. J. Kennel, M. Stabin, J. C. Roeske, L. J. Foote, P. K. Lankford et al., Radiotoxicity of Bismuth-213 Bound to Membranes of Monolayer and Spheroid Cultures of Tumor Cells, Radiation Research, vol.151, issue.3, p.244, 1999.

Å. M. Ballangrud, W. H. Yang, S. Palm, R. Enmon, P. E. Borchardt et al., Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids, Clinical Cancer Research, vol.10, issue.13, pp.4489-4497, 2004.

S. Lindegren, P. Albertsson, T. Bäck, H. Jensen, S. Palm et al., Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure, Cancer Biotherapy and Radiopharmaceuticals, vol.35, issue.6, pp.425-436, 2020.

M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman et al., Clinical Experience with -Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2007.

H. Andersson, E. Cederkrantz, T. Back, C. Divgi, J. Elgqvist et al., Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009.

A. Hallqvist, K. Bergmark, T. Bäck, H. Andersson, P. Dahm-kähler et al., Intraperitoneal ?-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations, Journal of Nuclear Medicine, vol.60, issue.8, pp.1073-1079, 2019.

H. Nakamae, D. S. Wilbur, D. K. Hamlin, M. S. Thakar, E. B. Santos et al., Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the -Emitting Radionuclides Bismuth-213 or Astatine-211, Cancer Research, vol.69, issue.6, pp.2408-2415, 2009.

J. J. Orozco, T. Bäck, A. Kenoyer, E. R. Balkin, D. K. Hamlin et al., Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, issue.18, pp.3759-3767, 2013.

T. Bäck, N. Chouin, S. Lindegren, H. Kahu, H. Jensen et al., Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated ?-Radioimmunotherapy with 211 At-MX35-F(ab?) 2 : Influence of Absorbed Tumor Dose and Effect on Long-Term Survival, Journal of Nuclear Medicine, vol.58, issue.4, pp.598-604, 2016.

M. Cherel, S. Gouard, J. Gaschet, C. Sai-maurel, F. Bruchertseifer et al., 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-1604, 2013.

N. Fichou, S. Gouard, C. Maurel, J. Barbet, L. Ferrer et al., Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model, Frontiers in Medicine, vol.2, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817464

C. Bailly, S. Gouard, M. Lacombe, P. Remaud-le-saëc, B. Chalopin et al., Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma, Oncotarget, vol.9, issue.10, pp.9061-9072, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01677118

C. Bailly, S. Gouard, F. Guérard, B. Chalopin, T. Carlier et al., What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, International Journal of Molecular Sciences, vol.20, issue.10, p.2564, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02141555

F. Guérard, L. Navarro, Y. Lee, A. Roumesy, C. Alliot et al., Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies, Bioorganic & Medicinal Chemistry, vol.25, issue.21, pp.5975-5980, 2017.

R. H. Larsen, S. Slade, and M. R. Zalutsky, Blocking [211At]Astatide Accumulation in Normal Tissues: Preliminary Evaluation of Seven Potential Compounds, Nuclear Medicine and Biology, vol.25, issue.4, pp.351-357, 1998.

I. Fernández, A. Peña, N. Del-teso, V. Pérez, J. Rodríguez-cuesta et al., Clinical biochemistry parameters in C57BL/6J mice after blood collection from the submandibular vein and retroorbital plexus, J. Am. Assoc. Lab. Anim. Sci. JAALAS, vol.49, pp.202-206, 2010.

B. Thoolen, R. R. Maronpot, T. Harada, A. Nyska, C. Rousseaux et al., Proliferative and Nonproliferative Lesions of the Rat and Mouse Hepatobiliary System, Toxicologic Pathology, vol.38, issue.7_suppl, pp.5S-81S, 2010.

K. S. Frazier, J. C. Seely, G. C. Hard, G. Betton, R. Burnett et al., Proliferative and Nonproliferative Lesions of the Rat and Mouse Urinary System, Toxicologic Pathology, vol.40, issue.4_suppl, pp.14S-86S, 2012.

L. S. Manning, J. D. Berger, H. L. O'donoghue, G. N. Sheridan, P. G. Claringbold et al., A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse, British Journal of Cancer, vol.66, issue.6, pp.1088-1093, 1992.

J. H. Turner, P. G. Claringbold, L. S. Manning, H. L. O'donoghue, J. D. Berger et al., Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment With Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation, JNCI Journal of the National Cancer Institute, vol.85, issue.18, pp.1508-1513, 1993.

M. A. Frassanito, L. Rao, M. Moschetta, R. Ria, L. Di-marzo et al., Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies, Leukemia, vol.28, issue.4, pp.904-916, 2013.

P. Sonneveld, E. De-wit, and P. Moreau, How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?, Critical Reviews in Oncology/Hematology, vol.112, pp.153-170, 2017.

W. Yang and S. Lin, Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma, BioMed Research International, vol.2015, pp.1-17, 2015.

M. Gao, Y. Kong, G. Yang, L. Gao, and J. Shi, Multiple myeloma cancer stem cells, Oncotarget, vol.7, issue.23, pp.35466-35477, 2016.

J. Abdi, H. Jian, and H. Chang, Role of micro-RNAs in drug resistance of multiple myeloma, Oncotarget, vol.7, issue.37, pp.60723-60735, 2016.

M. Roscher, I. Hormann, O. Leib, S. Marx, J. Moreno et al., Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells, Oncotarget, vol.4, issue.2, pp.218-230, 2013.

B. D. Yard, P. Gopal, K. Bannik, G. Siemeister, U. B. Hagemann et al., Cellular and Genetic Determinants of the Sensitivity of Cancer to ?-Particle Irradiation, Cancer Research, vol.79, issue.21, pp.5640-5651, 2019.

G. Sgouros, ?-Particle?Emitter Radiopharmaceutical Therapy: Resistance Is Futile, Cancer Research, vol.79, issue.21, pp.5479-5481, 2019.

J. Gorin, S. Gouard, J. Ménager, A. Morgenstern, F. Bruchertseifer et al., Alpha Particles Induce Autophagy in Multiple Myeloma Cells, Frontiers in Medicine, vol.2, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01817484

N. Chouin, K. Bernardeau, M. Bardiès, A. Faivre-chauvet, M. Bourgeois et al., Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. II. Application of the Microdosimetric Model to Experimental Results, Radiation Research, vol.171, issue.6, pp.664-673, 2009.

V. Hoyos and I. Borrello, The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies, Blood, vol.128, issue.13, pp.1679-1687, 2016.

D. W. Sherbenou, T. M. Mark, and P. Forsberg, Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future, Clinical Lymphoma Myeloma and Leukemia, vol.17, issue.9, pp.545-554, 2017.

A. Ghai, D. Maji, N. Cho, C. Chanswangphuwana, M. Rettig et al., Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma, Journal of Nuclear Medicine, vol.59, issue.2, pp.216-222, 2017.

J. L. Cannons, S. G. Tangye, and P. L. Schwartzberg, SLAM Family Receptors and SAP Adaptors in Immunity, Annual Review of Immunology, vol.29, issue.1, pp.665-705, 2011.

, SLAMF7 Gene, Tissue Expression of SLAMF7-Summary-The Human Protein Atlas, p.30, 2020.

I. Quelven, J. Monteil, M. Sage, A. Saidi, J. Mounier et al., 212Pb ?-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study, Journal of Nuclear Medicine, vol.61, issue.7, pp.1058-1065, 2019.

S. O?steen, M. L. Comstock, J. J. Orozco, D. K. Hamlin, D. S. Wilbur et al., The ?-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model, Blood, vol.134, issue.15, pp.1247-1256, 2019.

S. Gouard, A. Pallardy, J. Gaschet, A. Faivre-chauvet, F. Bruchertseifer et al., Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy, Nuclear Medicine and Biology, vol.41, pp.e30-e35, 2014.

C. Wu, L. Zhang, Q. R. Brockman, F. Zhan, and L. Chen, Chimeric antigen receptor T cell therapies for multiple myeloma, Journal of Hematology & Oncology, vol.12, issue.1, 2019.

R. F. Hobbs, R. W. Howell, H. Song, S. Baechler, and G. Sgouros, Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy, Radiation Research, vol.181, issue.1, pp.90-98, 2014.

L. Dorso, E. Bigot-corbel, J. Abadie, M. Diab, S. Gouard et al., Long-Term Toxicity of 213Bi-Labelled BSA in Mice, PLOS ONE, vol.11, issue.3, p.e0151330, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01809417

C. Rousseau, L. Ferrer, S. Supiot, M. Bardiès, F. Davodeau et al., Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumor Biology, vol.33, issue.3, pp.679-688, 2012.

L. Navarro, M. Berdal, M. Chérel, F. Pecorari, J. Gestin et al., Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies, Bioorganic & Medicinal Chemistry, vol.27, issue.1, pp.167-174, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01939636

K. F. Eckerman, A. Endo, and . Mird, Radionuclide Data and Decay Schemes, Society of Nuclear Medicine, 2008.